Steven A. Feldman

T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial

Daniel W Lee, James N. Kochenderfer, Maryalice Stetler‐Stevenson et al. · The Lancet · 2014 · 2.9K citations

Life Sciences, Hematology, Oncology +17

Tumor Regression in Patients With Metastatic Synovial Cell Sarcoma and Melanoma Using Genetically Engineered Lymphocytes Reactive With NY-ESO-1

Paul F. Robbins, Richard A. Morgan, Steven A. Feldman et al. · Journal of Clinical Oncology · 2011 · 1.6K citations · Full text

Life Sciences, Immunology, Oncology +17

Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma and Indolent B-Cell Malignancies Can Be Effectively Treated With Autologous T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor

James N. Kochenderfer, Mark E. Dudley, Sadik H. Kassim et al. · Journal of Clinical Oncology · 2014 · 1.6K citations · Full text

Medicine, Hematology, Oncology +17

B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor–transduced T cells

James N. Kochenderfer, Mark E. Dudley, Steven A. Feldman et al. · Blood · 2011 · 1.4K citations

Life Sciences, Hematology, Immunology +17

Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19

James N. Kochenderfer, Wyndham H. Wilson, John E. Janik et al. · Blood · 2010 · 1.3K citations · Full text

Medicine, Hematology, Oncology +14